^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | thalidomide (TNF inhibitor) + melphalan (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Thalidomide Celgene in combination with melphalan and prednisone as first-line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high-dose chemotherapy.
